StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Deferred tax assets by Year

Deferred tax assets — Net operating loss & tax credit carryforwards ($M) ($M)

Vertex Pharmaceuticals Deferred tax assets: $356M in FY2025, up 19.3% from a year earlier.

Latest, FY2025
356
Period ended Dec 31, 2025
Change on a year earlier
+19.3%
298 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-K Note (Income Taxes).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedDeferred tax assets — Net operating loss & tax credit carryforwards ($M) ($M)Year on yearSource
FY2025Dec 31, 2025356+19.3%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 2024298+14.3%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 2023261+17.0%Form 10-K (filed 2025-02-13) ↗
FY2022Dec 31, 2022223+10.2%Form 10-K (filed 2024-02-15) ↗
FY2021Dec 31, 2021202-50.2%Form 10-K (filed 2023-02-10) ↗
FY2020Dec 31, 2020406-26.1%Form 10-K (filed 2022-02-09) ↗
FY2019Dec 31, 2019550+12.7%Form 10-K (filed 2021-02-11) ↗
FY2018Dec 31, 2018488+10.7%Form 10-K (filed 2020-02-13) ↗
FY2017Dec 31, 2017440+19.9%Form 10-K (filed 2019-02-13) ↗
FY2016Dec 31, 2016367+16.5%Form 10-K (filed 2018-02-15) ↗
FY2015Dec 31, 2015316–Form 10-K (filed 2017-02-23) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Deferred tax assets ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/dta-tax-credits

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.